CAS 101622-51-9|Olomoucine
| Common Name | Olomoucine | ||
|---|---|---|---|
| CAS Number | 101622-51-9 | Molecular Weight | 298.343 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 579.6±60.0 °C at 760 mmHg |
| Molecular Formula | C15H18N6O | Melting Point | 120-130 °C |
| MSDS | ChineseUSA | Flash Point | 304.3±32.9 °C |
Names
| Name | 2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol |
|---|---|
| Synonym | More Synonyms |
Olomoucine BiologicalActivity
| Description | Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 µM), CDK/p35 kinase (IC50=3 µM) and ERK1/p44 MAP kinase (IC50=25 µM)[1][2]. |
|---|---|
| Related Catalog | Research Areas >>OthersSignaling Pathways >>Cell Cycle/DNA Damage >>CDK |
| Target | cdk2-cyclin A:7 μM (IC50) cdk2-cyclin E:7 μM (IC50) |
| References | [1]. Vesely, J., Havlicek, J., Strnad, M., et al. Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224, 771-786 (1994). [2]. 2.Abraham, R.T., Acquarone, M., Andersen, A., et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell 83(2), 105-120 (1995). |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 579.6±60.0 °C at 760 mmHg |
| Melting Point | 120-130 °C |
| Molecular Formula | C15H18N6O |
| Molecular Weight | 298.343 |
| Flash Point | 304.3±32.9 °C |
| Exact Mass | 298.154205 |
| PSA | 87.89000 |
| LogP | -0.08 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.691 |
| InChIKey | GTVPOLSIJWJJNY-UHFFFAOYSA-N |
| SMILES | Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21 |
| Storage condition | −20°C |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | S24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles5
More Articles| Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224 , 771, (1994) While testing purines related to the non-specific protein kinase inhibitors N6-dimethylaminopurine and N6-(delta 2-isopentenyl)adenine as potential inhibitors of the p34cdc2/cyclin B kinase, we discov... | |
| Steering neuronal growth cones by shifting the imbalance between exocytosis and endocytosis. J. Neurosci. 34(21) , 7165-78, (2014) Extracellular molecular cues guide migrating growth cones along specific routes during development of axon tracts. Such processes rely on asymmetric elevation of cytosolic Ca(2+) concentrations across... | |
| Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol. Cell 83 , 105-120, (1995) Olomoucine (2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine) has been recently described as a competitive inhibitor (ATP-binding site) of the cell cycle regulating p34cdc2/cyclin B, p33cdk2/cycli... |
Synonyms
| OLO |
| olomoucine |
| 2-{[6-(Benzylamino)-9-methyl-9H-purin-2-yl]amino}ethanol |
| Ethanol, 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]- |
| MFCD00189360 |
| Olomoucine,high purity |
| 2-(6-Benzylamino-9-methyl-9H-purin-2-ylamino)-ethanol Olomoucine |
